These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28100090)

  • 1. Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
    Ma Q; Chen YJ; Hines DM; Munakata J; Batty N; Barber BL; Zhao Z
    J Dermatolog Treat; 2017 Sep; 28(6):549-553. PubMed ID: 28100090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
    Chapman PB; Robert C; Larkin J; Haanen JB; Ribas A; Hogg D; Hamid O; Ascierto PA; Testori A; Lorigan PC; Dummer R; Sosman JA; Flaherty KT; Chang I; Coleman S; Caro I; Hauschild A; McArthur GA
    Ann Oncol; 2017 Oct; 28(10):2581-2587. PubMed ID: 28961848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.
    Patel SP; Kim DW; Bassett RL; Cain S; Washington E; Hwu WJ; Kim KB; Papadopoulos NE; Homsi J; Hwu P; Bedikian AY
    Cancer Immunol Immunother; 2017 Oct; 66(10):1359-1366. PubMed ID: 28612140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities].
    Koprowska K; Czyż M
    Postepy Hig Med Dosw (Online); 2011 Nov; 65():734-51. PubMed ID: 22173438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma.
    Lee D; Porter J; Hertel N; Hatswell AJ; Briggs A
    BioDrugs; 2016 Aug; 30(4):307-19. PubMed ID: 27177756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting.
    Toy EL; Vekeman F; Lewis MC; Oglesby AK; Duh MS
    Curr Med Res Opin; 2015 Aug; 31(8):1561-72. PubMed ID: 26086578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.
    Flaherty L; Hamid O; Linette G; Schuchter L; Hallmeyer S; Gonzalez R; Cowey CL; Pavlick A; Kudrik F; Curti B; Lawson D; Chapman PB; Margolin K; Ribas A; McDermott D; Flaherty K; Cranmer L; Hodi FS; Day BM; Linke R; Hainsworth J
    Cancer J; 2014; 20(1):18-24. PubMed ID: 24445759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns in advanced melanoma: findings from a survey of European oncologists.
    Jones C; Zhao Z; Barber B; Bagijn M; Corrie P; Saltman D
    Eur J Cancer Care (Engl); 2015 Nov; 24(6):862-6. PubMed ID: 25988349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current systemic therapies for melanoma.
    Palathinkal DM; Sharma TR; Koon HB; Bordeaux JS
    Dermatol Surg; 2014 Sep; 40(9):948-63. PubMed ID: 25072125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vemurafenib: in unresectable or metastatic melanoma.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study.
    Middleton MR; Dalle S; Claveau J; Mut P; Hallmeyer S; Plantin P; Highley M; Kotapati S; Le TK; Brokaw J; Abernethy AP
    Cancer Med; 2016 Jul; 5(7):1436-43. PubMed ID: 27118102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vemurafenib. Value unclear in metastatic melanoma.
    Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative healthcare costs in patients with metastatic melanoma in the USA.
    Chang CL; Schabert VF; Munakata J; Donga P; Abhyankar S; Reyes CM; Yim YM
    Melanoma Res; 2015 Aug; 25(4):312-20. PubMed ID: 25882026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upcoming strategies for the treatment of metastatic melanoma.
    Spagnolo F; Queirolo P
    Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival with modern therapeutic agents against metastatic melanoma-vemurafenib and ipilimumab in a daily life setting.
    Lang BM; Peveling-Oberhag A; Faidt D; Hötker AM; Weyer-Elberich V; Grabbe S; Loquai C
    Med Oncol; 2018 Jan; 35(3):24. PubMed ID: 29387968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2013-2016.
    Brzozowska M; Wierzba W; Śliwczyński A; Świerkowski M; Potemski P; Marczak M
    Melanoma Res; 2018 Feb; 28(1):52-55. PubMed ID: 29120964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2.
    Ma C; Armstrong AW
    J Dermatolog Treat; 2014 Oct; 25(5):401-8. PubMed ID: 23763243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice.
    Walker MS; Reyes C; Kerr J; Satram-Hoang S; Stepanski EJ
    Int J Dermatol; 2014 Nov; 53(11):e499-506. PubMed ID: 24602078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib.
    Seifert H; Fisher R; Martin-Liberal J; Edmonds K; Hughes P; Khabra K; Gore M; Larkin J
    Melanoma Res; 2016 Apr; 26(2):138-44. PubMed ID: 26684061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metastatic melanoma: some hope from ipilimumab and vemurafenib].
    Piérard-Franchimont C; Piérard GE
    Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.